UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA

VALUE DRUG COMPANY

Plaintiff,

- against -

TAKEDA PHARMACEUTICALS, U.S.A., INC., et al.,

Defendants.

Civil Action No.:

Related Case No.: 2:21-cv-03500-MAK¹

LARS TAAVOLA AND KEN CAPPEL'S MOTION TO QUASH SUBPOENA FOR PERSONAL PHONE RECORDS AND LOCATION DATA

Lars Taavola and Ken Cappel (together, "Movants"), pursuant to Fed. R. Civ. P. 45(d), hereby submit this Motion to Quash Value Drug Company's Subpoena to AT&T for Phone Records and Location Data, and in support states:

I. INTRODUCTION AND FACTUAL BACKGROUND

This motion seeks to quash a subpoena issued to AT&T Wireless ("AT&T") for phone records and location data of non-parties to an ongoing litigation in the Eastern District of Pennsylvania, *Value Drug Company v. Takeda Pharmaceuticals, U.S.A., Inc. et al.*, Case No. 2:21-cv-03500-MAK (the "Underlying Action"). Movants Lars Taavola and Ken Cappel are former in-house counsel of a Defendant in that case, Amneal Pharmaceuticals LLC ("Amneal"). The subpoena was issued by Value Drug Company ("Value Drug"), a wholesaler of pharmaceutical products that is the Plaintiff in the Underlying Action. Because the subpoena inappropriately seeks personal information of non-parties, and because such information is

As set forth herein, this Motion to Quash concerns a subpoena issued from the federal court in the Eastern District of Pennsylvania, but the place for compliance specified in the subpoenas is Miami, Florida. In accordance with Fed. R. Civ. P. 45(d)(3)(A), Messrs. Cappel and Taavola move this Court to quash the subpoenas, as it is the court for the district where compliance is required.

neither relevant nor proportional to the needs of the Underlying Action, Movants respectfully request this Court to quash Value Drug's subpoena, in its entirety.

The Underlying Action concerns a settlement agreement that resolved a patent litigation between Amneal and another pharmaceutical company, Takeda Pharmaceuticals U.S.A., Inc. Value Drug alleges that the settlement agreement between Takeda and Amneal was unlawful and anticompetitive. Value Drug alleges that the settlement between Takeda and Amneal was a part of a conspiracy between Takeda, Amneal, and two other generic pharmaceutical companies to restrict output of the drug colchicine. From August 2015 to January 2016, Movants were both involved in the settlement negotiations on behalf of Amneal.

The subpoena at issue was issued to non-party AT&T at 11760 US Hwy 1, Suite 600, North Palm Beach, FL 33408, seeking the phone records and location data of thirteen individuals, including Messrs. Taavola and Cappel. (See Declaration of Alexandra Russell ("Russell Decl."), Ex. 1 Subpoena). Value Drug gave no notice to either Mr. Taavola or Mr. Cappel that it had subpoenaed their personal cell phone records and location data. Mr. Taavola received notice from AT&T on November 12, 2022 that his records had been subpoenaed by a third-party. The time of compliance for the subpoena is November 18 at 9 a.m., which this Motion precedes.

Value Drug seeks vast amounts of information concerning Movants and the other individuals in the AT&T subpoena. Specifically, Value Drug seeks "Electronic specifications for all call, SMS, MMS, and data records for" each of the Movants' personal cell phone numbers, including outgoing and incoming phone numbers for *all* calls, date and time of call start and end for *all* calls, the length of *all* calls, the time zone of *all* calls, the location of the phone for *all* calls, and the type of phone for *all* calls. *See* Russell Decl. Ex. 1, at 8-9. Plaintiff

seeks this information for a period of almost *five years*. *Id*. (describing the "Relevant Time Period" as "January 9, 2015 through and including December 31, 2019"). At no point—within the subpoena, or otherwise—did Value Drug explain why such a vast swath of personal cell phone records and location data is relevant to any of the claims it alleges in the Underlying Action.

Recognizing the overbreadth of their subpoena and facing the threat of a similar Motion to Quash from another individual named in the subpoena, Dr. Paul Tully, Value Drug agreed to substantially narrow its request as to Dr. Tully *only*. *See* Russell Decl. Ex. 2, November 17, 2022 Email Exchange between Counsel for Value Drug and Counsel for Dr. Paul Tully. Specifically, Value Drug agreed, for Dr. Tully *only*, to not seek any location data, and to only seek information regarding phone calls *between* the individuals listed in the subpoena, instead of *all* calls made or received. *Id*. However, when Movants' counsel made a good faith effort to resolve this dispute by offering to Value Drug counsel to narrow the subpoena as to Movants and similarly situated individuals on the same terms that Value Drug had narrowed the subpoena as to Dr. Tully, counsel for Value Drug did not respond. *Id*. This Motion followed.

II. LEGAL STANDARD

"A motion to quash a subpoena is governed by Rule 45 of the Federal Rules of Civil Procedure." *Smith v. Pefanis*, 2008 WL 11333335, at *1 (N.D. Ga. Oct. 30, 2008). Discovery "is not an unlimited license for a fishing expedition." *Id.* "A court must quash or modify a subpoena that requires disclosure of privileged or other protected matter, if no exception or waiver applies." *Russell v. City of Tampa, Fla.*, 2017 WL 2869518, at *2 (M.D. Fla. July 5, 2017). "Further, a protective order may be issued for good cause to protect a person from annoyance, embarrassment, oppression, or undue burden or expense, by forbidding the discovery, forbidding inquiry into certain matters, or limiting the scope of disclosure or

III. ARGUMENT

A. Movants Have Standing to Challenge the Subpoena

"[N]umerous courts have held that parties have a personal interest in their financial and telephone records sufficient to confer standing to challenge a subpoena directed to a thirdparty." Keim v. ADF Midatlantic, LLC, 2016 WL 720967, at *2 (S.D. Fla. Feb. 22, 2016) (internal citations omitted) (finding that party had standing to challenge subpoena to his telephone carrier); see also Schmulovich v. 1161 Rt. 9 LLC, 2008 WL 4572537, at *4 (D.N.J. Oct. 14, 2008); Patrick Collins, Inc. v. John Does 1-13, 2013 WL 3466833, at *2 (D.N.J. July 10, 2013) (finding the defendant had third-party standing to challenge a subpoena to an internet provider because he asserted "personal and proprietary interests" in his subscriber information). Here, Messrs. Cappel and Taavola are the users of phones whose records are being sought and have privacy interests in the phone records and location data. Movants therefore have standing to challenge the subpoena. See Carpenter v. U.S., 138 S.Ct. 2206 (2018) (recognizing privacy interest in personal location data); Keim, 2016 WL 720967, at *2; Gilmore v. Jones, 2022 WL 267422, at *2 n.1 (D.N.J. Jan. 28, 2022) (recognizing that a movant had standing to challenge a subpoena seeking phone records because movant, as here, asserted "personal and proprietary interests in his phone records.").

B. The Subpoena Does Not Seek Relevant Information

As described above, the vast quantity of data Value Drug seeks in the subpoena are not relevant to any of Value Drug's claims in the Underlying Action. "Under Rule 45, courts have significant discretion to quash or modify a subpoena where the discovery sought is irrelevant, or compliance with the subpoena would be unreasonable or oppressive." *Malhan v. Grewal*, 2020

WL 6391180, at *3 (D.N.J. Nov. 2, 2020) (cleaned up).

Here, Value Drug seeks phone records and location data from the *personal* cell phones of Movants for a period of nearly *five years*. This is the definition of a fishing expedition and is inherently unreasonable. "Indeed, the subpoena's broad request for all phone records over the course of a year—without any subject-matter limitation—reveals just how unreasonable the subpoena is." *Gilmore*, 2022 WL 267422, at *2. The information and data Value Drug seeks from AT&T is private, sensitive information reflecting the personal lives of each Movant, which is not relevant in any way to Value Drug's claims. This type of information is not discoverable. *See Keim*, 2016 WL 720967, at *2 ("Defendants are not entitled to Plaintiff's and Ms. Worsena's entire telephone records since May 27, 2008 because Defendants have not made a showing that they are all relevant to the issues in this case...[f]or instance, telephone records of calls or text messages between Plaintiff and his mother are irrelevant to the issues in this case.").

Value Drug does not allege in any of its pleadings, or its subpoenas, that any of the Movants regularly engaged (or *ever* engaged) in any business discussions on their personal cell phones. Nor does Value Drug explain why any information concerning Movants' locations would have any bearing on any of its claims. What's more, even if Movants engaged in settlement negotiations on their personal cell phones during the course of settlement negotiations, the fact of those conversations is not probative at all of whether the ultimate settlement agreement was unlawful or not. Because Value Drug "nowhere explains how these phone records...will help establish" any of their claims, *see Gilmore*, 2022 WL 267422, at *2, Value Drug's subpoena must be quashed. *See id* (quashing subpoena for phone records due to a lack of relevance); *Smith*, 2008 WL 11333335, at *3 ("While defendants may be able to establish the relevance of some of plaintiff's phone records, they have not shown any reason that they

should be granted unrestricted access to plaintiff's entire personal cell phone records during the time period specified in the subpoena... Allowing defendants this unrestricted access exceeds the scope of reasonable discovery in this case.").

Even if Value Drug could establish that some narrow sliver of the subpoena is targeted at relevant material, the subpoena is still facially overbroad both temporally and substantively. Instead of narrowly targeting the few months near the end of 2015 when Amneal and Takeda were negotiating the settlement agreement, Value Drug instead seeks almost *five years* of phone records and location data. See Alton v. Liberty Med. Supply, Inc., 2007 WL 9702561, at *1 (S.D. Fla. Oct. 5, 2007) (rejecting request for telephone records as "temporally overbroad" when they sought phone records for one month following the relevant event). And instead of submitting a narrow request regarding phone records reflecting conversations between the negotiators only, Value Drug seeks records regarding all conversations. A subpoena with such a wide scope is untenable and, at a minimum, should be substantially narrowed. See Keim, 2016 WL 720967, at *2; Nationwide Mut. Ins. Co. v. Ft. Myers Total Rehab Ctr., Inc., 2010 WL 11507085, at *3 (M.D. Fla. Apr. 9, 2010) (holding that a "request for all cell phone records is overly broad"); Russell, 2017 WL 2869518, at *4 (M.D. Fla. July 5, 2017) (substantially narrowing subpoena for phone records to a two-hour relevant time span). In fact, this result is exactly what Value Drug itself agreed to for Dr. Tully—another Amneal negotiator—and there is no basis besides a motivation to harass Movants for Value Drug to insist on the overbroad and intrusive subpoena it refuses to limit with respect to the Movants.

If this Court elects not to quash the facially overbroad subpoena in its entirety, it should narrow the subpoena to the time period wherein settlement negotiations took place (August 2015 through January 2016) and should narrow the request for phone records to communications

between known negotiators.

IV. CERTIFICATE OF CONFERRAL UNDER S.D. FLA. L.R. 7.1(A)(3)

Pursuant to S.D. Fla. L.R. 7.1(a)(3), undersigned counsel has attempted to confer in good

faith with counsel for Value Drug in an effort to resolve this dispute without judicial

intervention, by offering on November 17, 2022 to Value Drug to narrow the subpoena on

identical terms to which Value Drug agreed to narrow the subpoena with respect to another

individual listed in the subpoena. See Russell Decl. Ex. 2. Because counsel for Value Drug did

not respond to undersigned counsel, the parties have been unable to resolve this dispute, and

judicial intervention is necessary.

V. CONCLUSION

For these reasons, this Court should quash the subpoena.

Dated: November 18, 2022

KIRKLAND & ELLIS LLP

By: /s/ Nadia Abramson

Nadia Abramson (FL Bar #121763)

Kirkland & Ellis LLP 300 North Lasalle

Chicago, Illinois 60654

Tel: 312-862-2484

nadia.abramson@kirkland.com

Devora Allon (pro hac vice forthcoming)

Alexandra I. Russell (pro hac vice forthcoming)

Gilad Bendheim (pro hac vice forthcoming)

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

Tel: 212-446-4800

devora.allon@kirkland.com

alexandra.russell@kirkland.com

gilad.bendheim@kirkland.com

Attorneys for Movants Ken Cappel and Lars

Taavola

7

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA

VALUE DRUG COMPANY

Civil Action No.:

Related Case No.: 2:21-cv-03500-MAK

- AGAINST -

TAKEDA PHARMACEUTICALS, U.S.A., INC., *ET AL.*,

Defendants.

Plaintiff,

I, Alexandra Russell, the undersigned, declare as follows:

1. I am a partner at the law firm of Kirkland & Ellis LLP, counsel for Movants Lars Taavola and Ken Cappel. I am fully familiar with the facts and circumstances of this action.

2. I submit this declaration, along with the exhibits annexed hereto, in support of Movants Lars Taavola and Ken Cappel's Motion to Quash Subpoena for Personal Phone Records and Location Data.

3. Annexed hereto as Exhibit 1 is a true and correct copy of Value Drug Company, Inc.'s Notice of Subpoena to AT&T, dated October 28, 2022.

4. Annexed hereto as Exhibit 2 is a true and correct copy of an email exchange between and among counsel for Lars Taavola and Ken Cappel, counsel for Value Drug Company, and counsel for Dr. Paul Tully.

Dated: November 18, 2022 /s/ Alexandra Russell

Alexandra Russell

EXHIBIT 1

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

VALUE DRUG COMPANY, on behalf of itself and all others similarly situated,

Plaintiff,

v.

TAKEDA PHARMACEUTICALS U.S.A., INC., et al.,

Defendants.

Civil Action No. 2:21-cv-03500-MAK

NOTICE OF SUBPOENAS DUCES TECUM TO AT&T AND VERIZON

PLEASE TAKE NOTICE THAT, pursuant to Rule 45 of Federal Rules of Civil

Procedure, subpoenas in the attached form will be served on the following:

AT&T Wireless Verizon Wireless

Dated: October 28, 2022 Respectfully submitted,

VALUE DRUG COMPANY

By: <u>/s/ Bradley J. Demuth</u> One of Its Attorneys

Bruce E. Gerstein
Dan Litvin
Deborah Elman (Pa. I.D. 87503)
David B. Rochelson

GARWIN GERSTEIN & FISHER LLP

88 Pine Street, 10th Floor New York, NY 10005 (212) 398-0055 bgerstein@garwingerstein.com dlitvin@garwingerstein.com delman@garwingerstein.com

David F. Sorensen (Pa. I.D. 57766)

drochelson@garwingerstein.com

Peter Kohn (Pa. I.D. 65454) Joseph Lukens (Pa. I.D. 67405) FARUQI & FARUQI LLP 1617 JFK Blvd, Suite 1550 Philadelphia, PA 19103 (215) 277-5770 pkohn@faruqilaw.com jlukens@faruqilaw.com

Bradley J. Demuth Raymond N. Barto FARUQI & FARUQI LLP 685 Third Avenue

New York, NY 10017

Caitlin G. Coslett (Pa. I.D. 306915) **BERGER MONTAGUE PC**

1818 Market Street, Suite 3600 Philadelphia, PA 19103 (215) 875-3000 dsorensen@bm.net ccoslett@bm.net

Susan Segura
David C. Raphael
Erin R. Leger
SMITH SEGURA RAPHAEL

LEGER LLP 221 Ansley Blvd. Alexandria, LA 71303 (318) 445-4480

ssegura@ssrllp.com draphael@ssrllp.com eleger@ssrllp.com (212) 983-9330 bdemuth@faruqilaw.com rbarto@faruqilaw.com

Stuart E. Des Roches Andrew W. Kelly **ODOM & DES ROCHES LLC** 650 Poydras Street, Suite 2020 New Orleans, LA 70130

(504) 522-0077 stuart@odrlaw.com akelly@odrlaw.com

Russell Chorush **HEIM PAYNE & CHORUSH LLP**

1111 Bagby Street, Suite 2100 Houston, TX 77002 (713) 221-2000 rchorush@hpcllp.com

Counsel for Plaintiff and the Proposed Class

CERTIFICATE OF SERVICE

I hereby certify that on October 28, 2022, I served the foregoing via email on the

following representative counsel for defendants:

Steven A. Reed R. Brendan Fee Melina R. DiMattio D. Patrick Huyett Vincent C. Papa MORGAN, LEWIS & BOCKIUS LLP

Attorneys for Defendant Takeda Pharmaceuticals U.S.A., Inc.

Dated: October 28, 2022

Devora W. Allon, P.C. Alexandra I. Russell Gilad Bendheim Jacob M. Rae KIRKLAND & ELLIS LLP

Attorneys for Defendants Watson Laboratories, Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd.

> /s/ Bradley J. Demuth Bradley J. Demuth

United States District Court

for the

Eastern District of Pennsylvania

Val	ue Drug Company)	
Takeda Pharn	Plaintiff V. naceuticals U.S.A., Inc., et al.) (Civil Action No. 2:21-cv-03500-MAK
	Defendant)	
S	UBPOENA TO PRODUCE DOCUM OR TO PERMIT INSPECTION O		
To:	·		Compliance Center, orth Palm Beach, FL 33408
_	(Name of person to	whom this	s subpoena is directed)
documents, electron material: See attac	nically stored information, or objects, as	nd to per	ne time, date, and place set forth below the following ermit inspection, copying, testing, or sampling of the
Place: 1441 Bricke	ell Avenue, Suite 1100, Miami FL 3313	1	Date and Time:
	herwise agreed upon)		11/18/2022 9:00 am
other property poss	essed or controlled by you at the time,	date, and	d location set forth below, so that the requesting party perty or any designated object or operation on it.
Place:		-	Date and Time:
Rule 45(d), relating respond to this subp	to your protection as a person subject poena and the potential consequences o	to a subp	ed – Rule 45(c), relating to the place of compliance; poena; and Rule 45(e) and (g), relating to your duty thing so.
Date: 10/28/202	22		
	CLERK OF COURT		
			OR
	Signature of Clerk or Deputy C	Clerk	/s/ Bradley Demuth Attorney's signature
			, ,
The name, address,	e-mail address, and telephone number	of the att	
Plaintiff			, who issues or requests this subpoena, are:

Notice to the person who issues or requests this subpoena

Bradley Demuth, Faruqi & Faruqi, LLP, 685 Third Ave, 26 FL, NY, NY, 10017, bdemuth@faruqilaw.com, 212.983.9330

If this subpoena commands the production of documents, electronically stored information, or tangible things or the inspection of premises before trial, a notice and a copy of the subpoena must be served on each party in this case before it is served on the person to whom it is directed. Fed. R. Civ. P. 45(a)(4).

Civil Action No. 2:21-cv-03500-MAK

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 45.)

(date)	bpoena for <i>(name of individual and title, if an</i>		
☐ I served the su	abpoena by delivering a copy to the nar	ned person as follows:	
		on (date) ;	or
☐ I returned the	subpoena unexecuted because:		
		States, or one of its officers or agents, I e, and the mileage allowed by law, in the	
fees are \$	for travel and \$	for services, for a total of \$	0.00
I declare under p	enalty of perjury that this information i	s true.	
e:		Server's signature	
		Printed name and title	
		Server's address	

Additional information regarding attempted service, etc.:

Federal Rule of Civil Procedure 45 (c), (d), (e), and (g) (Effective 12/1/13)

(c) Place of Compliance.

- (1) For a Trial, Hearing, or Deposition. A subpoena may command a person to attend a trial, hearing, or deposition only as follows:
- (A) within 100 miles of where the person resides, is employed, or regularly transacts business in person; or
- (B) within the state where the person resides, is employed, or regularly transacts business in person, if the person
 - (i) is a party or a party's officer; or
- (ii) is commanded to attend a trial and would not incur substantial expense.

(2) For Other Discovery. A subpoena may command:

- (A) production of documents, electronically stored information, or tangible things at a place within 100 miles of where the person resides, is employed, or regularly transacts business in person; and
 - **(B)** inspection of premises at the premises to be inspected.

(d) Protecting a Person Subject to a Subpoena; Enforcement.

(1) Avoiding Undue Burden or Expense; Sanctions. A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena. The court for the district where compliance is required must enforce this duty and impose an appropriate sanction—which may include lost earnings and reasonable attorney's fees—on a party or attorney who fails to comply.

(2) Command to Produce Materials or Permit Inspection.

- (A) Appearance Not Required. A person commanded to produce documents, electronically stored information, or tangible things, or to permit the inspection of premises, need not appear in person at the place of production or inspection unless also commanded to appear for a deposition, hearing, or trial.
- (B) Objections. A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection to inspecting, copying, testing, or sampling any or all of the materials or to inspecting the premises—or to producing electronically stored information in the form or forms requested. The objection must be served before the earlier of the time specified for compliance or 14 days after the subpoena is served. If an objection is made, the following rules apply:
- (i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.
- (ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party's officer from significant expense resulting from compliance.

(3) Quashing or Modifying a Subpoena.

- (A) When Required. On timely motion, the court for the district where compliance is required must quash or modify a subpoena that:
 - (i) fails to allow a reasonable time to comply;
- (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c);
- (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or
 - (iv) subjects a person to undue burden.
- **(B)** When Permitted. To protect a person subject to or affected by a subpoena, the court for the district where compliance is required may, on motion, quash or modify the subpoena if it requires:
- (i) disclosing a trade secret or other confidential research, development, or commercial information; or

- (ii) disclosing an unretained expert's opinion or information that does not describe specific occurrences in dispute and results from the expert's study that was not requested by a party.
- (C) Specifying Conditions as an Alternative. In the circumstances described in Rule 45(d)(3)(B), the court may, instead of quashing or modifying a subpoena, order appearance or production under specified conditions if the serving party:
- (i) shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship; and
 - (ii) ensures that the subpoenaed person will be reasonably compensated.

(e) Duties in Responding to a Subpoena.

- (1) *Producing Documents or Electronically Stored Information.* These procedures apply to producing documents or electronically stored information:
- (A) Documents. A person responding to a subpoena to produce documents must produce them as they are kept in the ordinary course of business or must organize and label them to correspond to the categories in the demand.
- **(B)** Form for Producing Electronically Stored Information Not Specified. If a subpoena does not specify a form for producing electronically stored information, the person responding must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms.
- (C) Electronically Stored Information Produced in Only One Form. The person responding need not produce the same electronically stored information in more than one form.
- **(D)** Inaccessible Electronically Stored Information. The person responding need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or for a protective order, the person responding must show that the information is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) Claiming Privilege or Protection.

- (A) Information Withheld. A person withholding subpoenaed information under a claim that it is privileged or subject to protection as trial-preparation material must:
 - (i) expressly make the claim; and
- (ii) describe the nature of the withheld documents, communications, or tangible things in a manner that, without revealing information itself privileged or protected, will enable the parties to assess the claim.
- **(B)** *Information Produced.* If information produced in response to a subpoena is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has; must not use or disclose the information until the claim is resolved; must take reasonable steps to retrieve the information if the party disclosed it before being notified; and may promptly present the information under seal to the court for the district where compliance is required for a determination of the claim. The person who produced the information must preserve the information until the claim is resolved.

(g) Contempt.

The court for the district where compliance is required—and also, after a motion is transferred, the issuing court—may hold in contempt a person who, having been served, fails without adequate excuse to obey the subpoena or an order related to it.

SCHEDULE A

I. <u>Definitions and Instructions</u>

- 1. The terms "all," "any," and "each" shall each be construed as encompassing any and all. The connectives "and" and "or" shall be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside of its scope. The use of the singular form of any word includes the plural and vice versa.
 - 2. "Subpoena" means this subpoena and any schedules or attachments thereto.
- 3. "AT&T" means AT&T Wireless and any of its predecessors, successors, present or former parents, subsidiaries, or affiliates, whether direct or indirect; and all directors, officers, partners, employees, agents, contractors, consultants, representatives, and attorneys of the foregoing, or any other Persons associated with or acting on behalf of the foregoing, or acting on behalf of any predecessors, successors, or affiliates of the foregoing.
 - 4. The "Telephone Numbers" for which this Subpoena seeks information are:

Phone numbers	Name of associated individuals	Possible corporate affiliations
(201) 852-1136	Cappel, Kenneth	Amneal
(917) 701-6495	Taavola, Lars	Amneal
(847) 910-7092	Tully, Paul	McDonnell Boehnen
(847) 650-9810	Buonaiuto, Mark	Takeda
(847) 946-8382	Maxwell, Jason	Takeda
(323) 533-7531	Takahashi, Heather	Munger Tolles
(310) 991-8384	Weinberger, Jeffrey	Munger Tolles
(862) 210-5592	Leitch, Nathalie	Actavis
		Teva
(609) 462-8886	Motto, Daniel	Actavis
		Teva
(973) 610-7036	Spataro, Victoria	Actavis
(201) 841-2318		Teva
(202) 857-6232	Berman, Richard	Arent Fox

(201) 310-7398	Brown, Lawrence	Par Pharmaceutical
(908) 432-5075	***	Endo
(917) 683-3920		
(201) 749-7856	Campanelli, Paul	Par Pharmaceutical
(908) 432-5075		Endo
(914) 263-9250		

- The "Relevant Time Period" for which this Subpoena seeks information is
 January 9, 2015 through and including December 31, 2019.
- 6. The affidavit provided herewith shall be completed and executed by all natural persons supervising and/or participating in the compliance with this Subpoena, and a copy of each such executed affidavit shall be provided in response to this Subpoena.

II. Documents to be Produced

Electronic specifications for all call, SMS, MMS, and data records for all
 Telephone Numbers identified in Definition and Instruction No. 4 above, including:

FIELD NAME ¹	FIELD DESCRIPTION	FIELD VALUE EXAMPLE
RECID	Unique record identifier	ABC0001 or ###.################################
CALLFROM	Phone number initiating the call	123-555-1212
CALLTO	Phone number receiving the call	123-555-1212
DATETIMESTART	Date and time of call start	04-DEC-14 08.35.15 AM
DATETIMEEND	Date and time of call end	04-DEC-14 08.35.15 AM
DURATION	Length of call	hh:mm:ss
TIMEZONE	Time of zone of start/end date time	GMT/EST/CST

¹ For SMS or MMS messages, other or additional Field Name electronic specifications may be more appropriate to include such as those that identify whether a given message was SMS or MMS, the time the SMS or MMS message was sent/received, and/or the total size of the SMS or MMS message sent/received (*i.e.*, total characters and/or total KB or MB).

2

TIMEZONEOFFSET	Time zone of start/end date time	UTC offset, e.g., -5:00
LOCATION	Location of phone or mobile	Philadelphia, PA OR GPS coordinates **Not Required if not available**
PHONETYPE	Type of phone	Mobile, Fax, Office **Not Required if not available**

(NOTE: Delimiter should be pipe (|) no qualifier)

2. Subscriber information, including subscriber name(s) and billing address(es), for all Telephone Numbers identified in Definition and Instruction No. 4 above, including documents sufficient to show changes to any such subscriber information over the Relevant Time Period.

AFFIDAVIT OF COMPLIANCE WITH SUBPOENA

	State of}	
	County of}	
	I,, being	duly sworn, state as follows:
1.	I am employed by AT&T Wireless ("AT&T") in	the position of;
2.	AT&T's productions and responses to the subpo	ena dated October 2, 2019
	from plaintiffs in In re Zetia (Ezetimibe) Antitrus	st Litigation, 18-md-2836
	(E.D. Va.) (the "Subpoena") were prepared and	assembled under my
	personal supervision;	
3.	I made or caused to be made a diligent, complete	e, and comprehensive search for
	all documents and information requested by the	Subpoena, in full accordance
	with the instructions and definitions set forth in	the Subpoena;
4.	AT&T's productions and responses to the Subpo	pena are complete and
	correct to the best of my knowledge and belief;	
5.	No documents responsive to the Subpoena have	been withheld from AT&T's
	production and response, other than responsive of	documents withheld on the basis
	of a legal privilege or doctrine;	
6.	All responsive documents withheld on the basis	of a legal privilege or doctrine
	have been identified on a privilege log produced	in response to the Subpoena;
7.	The documents contained in Respondent's produ	actions and responses to the

as such, are authentic, genuine and what they purport to be; 8. Attached is a true and accurate record of all persons who prepared and assembled any productions and responses to the Subpoena, all persons under whose personal supervision the preparation and assembly of productions and responses to the Subpoena occurred, and all persons able competently to testify: (a) that such productions and responses are complete and correct to the best of such person's knowledge and belief; and (b) that any documents produced are authentic, genuine, and what they purport to be; and 9. Attached is a true and accurate statement of those requests under the Subpoena as to which responsive documents were located in the course of the aforementioned search. Signature of Affiant Date Subscribed and sworn before me this ____ day of _______, 2019. , Notary Public My commission expires:

Subpoena are records kept in the regular course of Respondent's business and,

United States District Court

for the

Eastern District of Pennsylvania

Valu	e Drug Company)		
Takeda Pharma	Plaintiff v. aceuticals U.S.A., Inc., et. al.)	Civil Action No.	2:21-cv-03500-MAK
	Defendant)		
SI	JBPOENA TO PRODUCE DOCU OR TO PERMIT INSPECTION			
To:	Verizon Wireless, Attn: VSAT, 180	Washingto	on Valley Road, E	Bedminster, NJ 07921
-	(Name of person	to whom this	subpoena is directed	d)
documents, electronic material: See attack	YOU ARE COMMANDED to proceed to cally stored information, or objects ned Schedule A.	and to per	e time, date, and mit inspection, c	copying, testing, or sampling of the
Place: 685 Third Av	venue, 26 FL, New York, NY 10017		Date and Time:	
(or place otherwise agreed upon)			11/18/2022 9:00 am	
other property posse	f Premises: YOU ARE COMMAN ssed or controlled by you at the time, survey, photograph, test, or samp	e, date, and le the prop	l location set fort	h below, so that the requesting party
Rule 45(d), relating	ng provisions of <u>Fed. R. Civ. P. 45</u> ato your protection as a person subjection and the potential consequences	ct to a subp	ooena; and Rule 4	lating to the place of compliance; 45(e) and (g), relating to your duty to
40/00/000	•	s of not doi	ng so.	
Date: 10/28/202	2			
	CLERK OF COURT			
			OR	/s/ Bradley Demuth
	Signature of Clerk or Deput	y Clerk		Attorney's signature
				· · ·
The name, address, e	e-mail address, and telephone numb	er of the at	• •	
Direct Purchaser Plai	ntiffs		, who issu	es or requests this subpoena, are:
Bradley Demuth, Fa	ruqi & Faruqi, LLP, 685 Third Ave, 2	26 FL, NY,	NY, 10017, bden	nuth@farugilaw.com, 212.983.9330

Notice to the person who issues or requests this subpoena

If this subpoena commands the production of documents, electronically stored information, or tangible things or the inspection of premises before trial, a notice and a copy of the subpoena must be served on each party in this case before it is served on the person to whom it is directed. Fed. R. Civ. P. 45(a)(4).

Civil Action No. 2:21-cv-03500-MAK

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 45.)

(date)	bpoena for <i>(name of individual and title, if an</i>		
☐ I served the su	abpoena by delivering a copy to the nar	ned person as follows:	
		on (date) ;	or
☐ I returned the	subpoena unexecuted because:		
		States, or one of its officers or agents, I e, and the mileage allowed by law, in the	
fees are \$	for travel and \$	for services, for a total of \$	0.00
I declare under p	enalty of perjury that this information i	s true.	
e:		Server's signature	
		Printed name and title	
		Server's address	

Additional information regarding attempted service, etc.:

Federal Rule of Civil Procedure 45 (c), (d), (e), and (g) (Effective 12/1/13)

(c) Place of Compliance.

- (1) For a Trial, Hearing, or Deposition. A subpoena may command a person to attend a trial, hearing, or deposition only as follows:
- (A) within 100 miles of where the person resides, is employed, or regularly transacts business in person; or
- (B) within the state where the person resides, is employed, or regularly transacts business in person, if the person
 - (i) is a party or a party's officer; or
- (ii) is commanded to attend a trial and would not incur substantial expense.

(2) For Other Discovery. A subpoena may command:

- (A) production of documents, electronically stored information, or tangible things at a place within 100 miles of where the person resides, is employed, or regularly transacts business in person; and
 - **(B)** inspection of premises at the premises to be inspected.

(d) Protecting a Person Subject to a Subpoena; Enforcement.

(1) Avoiding Undue Burden or Expense; Sanctions. A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena. The court for the district where compliance is required must enforce this duty and impose an appropriate sanction—which may include lost earnings and reasonable attorney's fees—on a party or attorney who fails to comply.

(2) Command to Produce Materials or Permit Inspection.

- (A) Appearance Not Required. A person commanded to produce documents, electronically stored information, or tangible things, or to permit the inspection of premises, need not appear in person at the place of production or inspection unless also commanded to appear for a deposition, hearing, or trial.
- (B) Objections. A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection to inspecting, copying, testing, or sampling any or all of the materials or to inspecting the premises—or to producing electronically stored information in the form or forms requested. The objection must be served before the earlier of the time specified for compliance or 14 days after the subpoena is served. If an objection is made, the following rules apply:
- (i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.
- (ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party's officer from significant expense resulting from compliance.

(3) Quashing or Modifying a Subpoena.

- (A) When Required. On timely motion, the court for the district where compliance is required must quash or modify a subpoena that:
 - (i) fails to allow a reasonable time to comply;
- (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c);
- (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or
 - (iv) subjects a person to undue burden.
- **(B)** When Permitted. To protect a person subject to or affected by a subpoena, the court for the district where compliance is required may, on motion, quash or modify the subpoena if it requires:
- (i) disclosing a trade secret or other confidential research, development, or commercial information; or

- (ii) disclosing an unretained expert's opinion or information that does not describe specific occurrences in dispute and results from the expert's study that was not requested by a party.
- (C) Specifying Conditions as an Alternative. In the circumstances described in Rule 45(d)(3)(B), the court may, instead of quashing or modifying a subpoena, order appearance or production under specified conditions if the serving party:
- (i) shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship; and
 - (ii) ensures that the subpoenaed person will be reasonably compensated.

(e) Duties in Responding to a Subpoena.

- (1) *Producing Documents or Electronically Stored Information.* These procedures apply to producing documents or electronically stored information:
- (A) Documents. A person responding to a subpoena to produce documents must produce them as they are kept in the ordinary course of business or must organize and label them to correspond to the categories in the demand.
- **(B)** Form for Producing Electronically Stored Information Not Specified. If a subpoena does not specify a form for producing electronically stored information, the person responding must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms.
- (C) Electronically Stored Information Produced in Only One Form. The person responding need not produce the same electronically stored information in more than one form.
- **(D)** Inaccessible Electronically Stored Information. The person responding need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or for a protective order, the person responding must show that the information is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) Claiming Privilege or Protection.

- (A) Information Withheld. A person withholding subpoenaed information under a claim that it is privileged or subject to protection as trial-preparation material must:
 - (i) expressly make the claim; and
- (ii) describe the nature of the withheld documents, communications, or tangible things in a manner that, without revealing information itself privileged or protected, will enable the parties to assess the claim.
- **(B)** *Information Produced.* If information produced in response to a subpoena is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has; must not use or disclose the information until the claim is resolved; must take reasonable steps to retrieve the information if the party disclosed it before being notified; and may promptly present the information under seal to the court for the district where compliance is required for a determination of the claim. The person who produced the information must preserve the information until the claim is resolved.

(g) Contempt.

The court for the district where compliance is required—and also, after a motion is transferred, the issuing court—may hold in contempt a person who, having been served, fails without adequate excuse to obey the subpoena or an order related to it.

SCHEDULE A

I. <u>Definitions and Instructions</u>

- 1. The terms "all," "any," and "each" shall each be construed as encompassing any and all. The connectives "and" and "or" shall be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside of its scope. The use of the singular form of any word includes the plural and vice versa.
 - 2. "Subpoena" means this subpoena and any schedules or attachments thereto.
- 3. "Verizon" means Verizon Wireless and any of its predecessors, successors, present or former parents, subsidiaries, or affiliates, whether direct or indirect; and all directors, officers, partners, employees, agents, contractors, consultants, representatives, and attorneys of the foregoing, or any other Persons associated with or acting on behalf of the foregoing, or acting on behalf of any predecessors, successors, or affiliates of the foregoing.
 - 4. The "Telephone Numbers" for which this Subpoena seeks information are:

Phone numbers	Name of associated individuals	Possible corporate affiliations
(201) 852-1136	Cappel, Kenneth	Amneal
(917) 701-6495	Taavola, Lars	Amneal
(847) 910-7092	Tully, Paul	McDonnell Boehnen
(847) 650-9810	Buonaiuto, Mark	Takeda
(847) 946-8382	Maxwell, Jason	Takeda
(323) 533-7531	Takahashi, Heather	Munger Tolles
(310) 991-8384	Weinberger, Jeffrey	Munger Tolles
(862) 210-5592	Leitch, Nathalie	Actavis
		Teva
(609) 462-8886	Motto, Daniel	Actavis
		Teva
(973) 610-7036	Spataro, Victoria	Actavis
(201) 841-2318		Teva
(202) 857-6232	Berman, Richard	Arent Fox

(201) 310-7398	Brown, Lawrence	Par Pharmaceutical
(908) 432-5075	***	Endo
(917) 683-3920		
(201) 749-7856	Campanelli, Paul	Par Pharmaceutical
(908) 432-5075		Endo
(914) 263-9250		

- The "Relevant Time Period" for which this Subpoena seeks information is
 January 9, 2015 through and including December 31, 2019.
- 6. The affidavit provided herewith shall be completed and executed by all natural persons supervising and/or participating in the compliance with this Subpoena, and a copy of each such executed affidavit shall be provided in response to this Subpoena.

II. Documents to be Produced

Electronic specifications for all call, SMS, MMS, and data records for all
 Telephone Numbers identified in Definition and Instruction No. 4 above, including:

FIELD NAME ¹	FIELD DESCRIPTION	FIELD VALUE EXAMPLE
RECID	Unique record identifier	ABC0001 or ###.################################
CALLFROM	Phone number initiating the call	123-555-1212
CALLTO	Phone number receiving the call	123-555-1212
DATETIMESTART	Date and time of call start	04-DEC-14 08.35.15 AM
DATETIMEEND	Date and time of call end	04-DEC-14 08.35.15 AM
DURATION	Length of call	hh:mm:ss
TIMEZONE	Time of zone of start/end date time	GMT/EST/CST

¹ For SMS or MMS messages, other or additional Field Name electronic specifications may be more appropriate to include such as those that identify whether a given message was SMS or MMS, the time the SMS or MMS message was sent/received, and/or the total size of the SMS or MMS message sent/received (*i.e.*, total characters and/or total KB or MB).

2

TIMEZONEOFFSET	Time zone of start/end date time	UTC offset, e.g., -5:00
LOCATION	Location of phone or mobile	Philadelphia, PA OR GPS coordinates **Not Required if not available**
PHONETYPE	Type of phone	Mobile, Fax, Office **Not Required if not available**

(NOTE: Delimiter should be pipe (|) no qualifier)

2. Subscriber information, including subscriber name(s) and billing address(es), for all Telephone Numbers identified in Definition and Instruction No. 4 above, including documents sufficient to show changes to any such subscriber information over the Relevant Time Period.

AFFIDAVIT OF COMPLIANCE WITH SUBPOENA

	State of}
	County of}
	I,, being duly sworn, state as follows:
1.	I am employed by Verizon Wireless ("Verizon") in the position of;
2.	Verizon's productions and responses to the subpoena dated October 2, 2019
	from plaintiffs in In re Zetia (Ezetimibe) Antitrust Litigation, 18-md-2836
	(E.D. Va.) (the "Subpoena") were prepared and assembled under my
	personal supervision;
3.	I made or caused to be made a diligent, complete, and comprehensive search for
	all documents and information requested by the Subpoena, in full accordance
	with the instructions and definitions set forth in the Subpoena;
4.	Verizon's productions and responses to the Subpoena are complete and
	correct to the best of my knowledge and belief;
5.	No documents responsive to the Subpoena have been withheld from Verizon's
	production and response, other than responsive documents withheld on the basis
	of a legal privilege or doctrine;
6.	All responsive documents withheld on the basis of a legal privilege or doctrine
	have been identified on a privilege log produced in response to the Subpoena;
7.	The documents contained in Respondent's productions and responses to the

as such, are authentic, genuine and what they purport to be; 8. Attached is a true and accurate record of all persons who prepared and assembled any productions and responses to the Subpoena, all persons under whose personal supervision the preparation and assembly of productions and responses to the Subpoena occurred, and all persons able competently to testify: (a) that such productions and responses are complete and correct to the best of such person's knowledge and belief; and (b) that any documents produced are authentic, genuine, and what they purport to be; and 9. Attached is a true and accurate statement of those requests under the Subpoena as to which responsive documents were located in the course of the aforementioned search. Signature of Affiant Date Subscribed and sworn before me this ____ day of _______, 2019. , Notary Public My commission expires:

Subpoena are records kept in the regular course of Respondent's business and,

EXHIBIT 2

From: Rae, Jacob M.

To: Rich, Joshua; Bradley J. Demuth

Cc: Russell, Alexandra I.; bfee@morganlewis.com; DiMattio, Melina R.; ColcrysPlaintiffs; Bendheim, Gilad; McCarty,

<u>Andrew</u>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless (File No. 3558328)

Date: Thursday, November 17, 2022 1:31:16 PM

Attachments: <u>image001.png</u>

image002.png image003.png image004.png

Brad.

For all the reasons articulated by Mr. Rich below, Victoria Spataro, Lars Taavola, and Kenneth Cappel have been planning to file Motions to Quash both the AT&T Subpoena and the Verizon Subpoena. Given Plaintiff's willingness to agree to the limitations proposed by Dr. Tully, however, Ms. Spataro, Mr. Taavola, and Mr. Cappel would be willing to agree not to file such a motion if Plaintiff agrees to similar limitations on the scope of subpoenas as to the phone numbers associated with current or former employees of Teva/Actavis and Amneal (Ms. Spataro, Ms. Leitch, and Messrs. Motto, Taavola, and Cappel).

Please let us know by 4 PM ET today whether Plaintiff agrees to narrow the AT&T and Verizon subpoenas as to the Amneal and Teva/Actavis individuals on the same terms as it has agreed to limit the AT&T subpoena for Dr. Tully.

Best,

Jacob Rae

he/him/his

KIRKLAND & ELLIS LLP

601 Lexington Avenue, New York, NY 10022 **T** +1 212 390 4516 **M** +1 610 299 9368

F +1 212 446 4900

iacob.rae@kirkland.com

From: Rich, Joshua < rich@mbhb.com>

Sent: Thursday, November 17, 2022 11:51 AM **To:** Bradley J. Demuth bdemuth@faruqilaw.com

Cc: Rae, Jacob M. <jacob.rae@kirkland.com>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

< melina. dimattio@morganlewis.com>; ColcrysPlaintiffs < ColcrysPlaintiffs@garwingerstein.com>;

Bendheim, Gilad <gilad.bendheim@kirkland.com>

Subject: Value Drug v. Takeda: Subpoena upon AT&T Wireless (File No. 3558328)

This message is from an EXTERNAL SENDER

Be cautious, particularly with links and attachments.

Counsel,

AT&T Wireless has asked that a copy of the agreement narrowing the subpoena come from your email address, since you served the subpoena. You can simply forward this message to gldc@att.com, but please ensure that the file number remains on the message so they know which account is at issue. Please also copy me on the message.

The parties have agreed to narrow the subpoena as follows with regard to the account of Paul Tully (phone number 847-910-7092). Note that this agreement does not affect any other account or number. AT&T Wireless may have additional time, if necessary, to respond to the subpoena to the extent that this amendment requires additional work by AT&T Wireless.

AT&T Wireless's response to the subpoena should be limited to only transmissions (calls or texts) between Dr. Tully's number and the other numbers identified in the subpoena, namely:

201-852-1136

917-701-6495

847-650-9810

847-946-8382

323-533-7531

310-991-8384

862-210-5592

609-462-8886

973-610-7036

201-841-2318

202-857-6232

201-310-7398

201 310 7330

908-432-5075 917-683-3920

201-749-7856

908-432-5075

914-263-9250

The fields provided shall not include LOCATION, but shall include all other requested fields (RECID, CALLFROM, CALLTO, DATETIMESTART, DATETIMEEND, DURATION, TIMEZONE, TIMEZONEOFFSET, PHONETYPE).

No other transmissions to or from Dr. Tully's phone (phone number 847-910-7092) should be included in the response to the subpoena. No content from any transmission should be included in the response to the subpoena.

Regards,

Joshua Rich

logo



Joshua Rich | Partner and General Counsel d: 312.913.2133 | o: 312.913.0001 300 S. Wacker Drive | Chicago, IL 60606 Mansfield Rule Participating Firm

From: Rich, Joshua

Sent: Thursday, November 17, 2022 10:16 AM **To:** Bradley J. Demuth < bdemuth@faruqilaw.com>

Cc: Rae, Jacob M. < <u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>;

Bendheim, Gilad <gilad.bendheim@kirkland.com>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

Counsel,

We agree on these terms. We will contact AT&T Wireless.

Regards,

Joshua Rich

logo



Joshua Rich | Partner and General Counsel d: 312.913.2133 | o: 312.913.0001 300 S. Wacker Drive | Chicago, IL 60606 Mansfield Rule Participating Firm

From: Bradley J. Demuth < <u>bdemuth@faruqilaw.com</u>>

Sent: Thursday, November 17, 2022 10:10 AM

To: Rich, Joshua < rich@mbhb.com>

Cc: Rae, Jacob M. < <u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

Plaintiff will agree to provide Dr. Tully notice of any subpoena seeking a further search of AT&T's records for (847) 910-7092 – i.e., in the event other relevant numbers are discovered.

Please confirm our accord.

From: Rich, Joshua < <u>rich@mbhb.com</u>>

Sent: Thursday, November 17, 2022 11:01 AM **To:** Bradley J. Demuth < bdemuth@farugilaw.com>

Cc: Rae, Jacob M. <<u>iacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

CAUTION: This Message originated from outside of the firm. Do not click on a link, open or enable any file unless you trust the sender.

Counsel,

We are willing to agree to these amendments to the proposal we provided if Plaintiff agrees that it will provide notice to Dr. Tully at the time of service of any other subpoena that would implicate his communications (as reserved by Plaintiff's statement that the agreement would be without prejudice to additional searches should additional relevant numbers be discovered).

Please confirm Plaintiff's agreement to this additional term.

Regards,

Joshua Rich



Joshua R. Rich [] Partner and General Counsel 300 South Wacker Drive [] Chicago, Illinois 60606-6709 312-913-2133 direct [] 312-913-0001 main [] 312-913-0002 fax rich@mbhb.com [] www.mbhb.com

From: Bradley J. Demuth < bdemuth@farugilaw.com >

Sent: Thursday, November 17, 2022 9:55 AM

To: Rich, Joshua < <u>rich@mbhb.com</u>>

Cc: Rae, Jacob M. < <u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

Mr. Rich: Thank you for the courtesy of your email and proposed compromise. In the spirit of good faith and to avoid further dispute, Plaintiffs will agree, only as an specific accommodation to Dr. Tully and only as applied to AT&T's search of the records for Dr. Tully's cell number (847) 910-7092 (but not to its searches of the other numbers in the subpoena) to the following:

- 1. Plaintiff will agree to limit AT&T's present search of the records for (847) 910-7092 to only the other numbers listed in the subpoena -- such agreement would be without prejudice to additional searches should additional relevant numbers be discovered;
- 2. Plaintiff will agree, with respect to the requested FIELD NAME searches of the records for (847) 910-7092, to forgo only the requested FIELD NAME LOCATION data everything else requested in the subpoena will be produced for (847) 910-7092 as requested; and
- 3. Plaintiff will agree to an extension of time, if needed, for AT&T to redo only its search of the records for (847) 910-7092, consistent with the above AT&T would otherwise timely produce all the other records requested in the subpoena for all the other numbers.

Since your proposal does not neatly correspond with the specifications in Plaintiff's subpoena, a couple of additional clarifications:

Plaintiff's subpoena seeks specific Field Name data for both calls and text messages – i.e., all *communications* made to/from the (847) 910-7092. AT&T does not maintain text message content so that is not an issue. But the fact of a text message exchange is relevant evidence. Your proposal does not expressly address text message records, but the above agreement clarifies that AT&T will be producing its records for both calls and text messages to/from (847) 910-7092.

In addition, the general "location" information Plaintiff requested in the subpoena was also requested in Brooks, which came after and cites to and therefore is not superseded by Carpenter. That said, given Plaintiff's above agreement and accommodation to forgo production of the Location data for (847) 910-7092, we need not belabor the point. The above agreement clarifies that AT&T will be producing all requested records and information for (847) 910-7092 for both calls and text messages to/from any of the other numbers except not the requested Location Field Name data.

Please confirm Dr. Tully's accord.

Best, Brad

From: Rich, Joshua <<u>rich@mbhb.com</u>>

Sent: Thursday, November 17, 2022 8:25 AM **To:** Bradley J. Demuth bdemuth@farugilaw.com

Cc: Rae, Jacob M. < <u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <ColcrysPlaintiffs@garwingerstein.com>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

CAUTION: This Message originated from outside of the firm. Do not click on a link, open or enable any file unless you trust the sender.

Counsel,

Please respond to the offer in this message by noon. We will otherwise have to move to quash unless Plaintiff agrees in writing to request an extension of time for the response to the subpoena, which may (or may not) extend the time for negotiation.

Dr. Tully is willing to agree to allow AT&T Wireless to provide the record identifier, initiating phone number, receiving phone number, date and time of call/transmission initiation, and date and time of call/transmission termination for transmissions only to the other numbers set forth in the subpoena. With such a subject matter limitation, we will not insist on a date limitation. If that is an acceptable scope to Plaintiff, please convey that message to us in writing so we can forward the narrowed scope to AT&T Wireless.

With regard to the case law and purported confusion on Plaintiff's part set forth below, the U.S. Supreme Court's 2018 decision in *Carpenter v. US* superseded the grounds for the *AF Holdings* case and establishes that an individual does have standing to challenge the production of information (including specifically location data, which Plaintiff has requested here) despite it being in the hands of a third-party telephone service provider. To the extent that the *Brooks* case is also denied standing on the basis of the third-party doctrine, it is clearly wrongly decided. But both are based on the fact that the subpoenas were narrowly drawn to obtain only information at issue in the cases. That is not the case here – the vast majority of information responsive to the subpoena as served relates to personal transmissions (and to a lesser extent, transmissions to other clients), none of which is at issue here.

We hope that our suggested narrowing of the scope of the subpoena to the transmissions that are within the scope of the issues here meets your agreement promptly so we can inform AT&T Wireless. We also ask that you agree in the same message to an extension of time, if needed, for AT&T Wireless to re-run its search for responsive documents to comply with the subpoena.

Regards,

Joshua Rich



Joshua R. Rich [] Partner and General Counsel 300 South Wacker Drive [] Chicago, Illinois 60606-6709 312-913-2133 direct [] 312-913-0001 main [] 312-913-0002 fax

From: Bradley J. Demuth < bdemuth@faruqilaw.com>
Sent: Wednesday, November 16, 2022 10:45 PM

To: Rich, Joshua < rich@mbhb.com>

Cc: Rae, Jacob M. <<u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

Mr. Rich: Apologies for not be able to respond sooner.

If you have a proposal to "potentially . . . narrow the request," please do so. Plaintiff is more than happy to make a reasonable accommodation that does not limit its ability to assess the conspiracy-related communications made to/from (847) 910-7092 during the 2015-2019 time period. Plaintiff is available to meet and confer to that end.

So that the record is clear, below are some additional responsive points to the issues you have most recently raised:

The email thread you appended below has apparently been altered to omit Plaintiff's November 15, 2022 response, which I have attached here.

Your reliance on Carpenter v. US, <u>138 S. Ct. 2206</u> (2018), is puzzling, as that case specifically concerned the government's need for a warrant to issue a subpoena seeking the carrier's highly detailed "cell/site sector" information, capable of pinpointing a person's location within 50 meters. It did not concern, as is at issue here, a subpoena principally seeking the dates, times, and duration of phone calls made and the phone numbers involved. Regarding such at-issue information, Dr. Tully "has no reasonable expectation of privacy." U.S. v. Brooks, 841 Fed. App. 346, 347, 350 (3d Cir. 2020) (upholding subpoenas for telephone records and flight information).

The subpoena is not directed to Dr. Tully, but rather AT&T, and AT&T confirmed via phone today that it had no objections to the subpoena and would make the requested production. Accordingly, Dr. Tully does not have standing to challenge the subpoena on grounds of undue burden or expense. AF Holdings, LLC v. Does 1-162, 2012 WL 488217, at *3 & n.1 (S.D. Fla. 2012) ("Putting aside the absence of authority to quash, the Court also finds that the Doe Defendant lacks standing to contest this subpoena. The subpoena was issued to Verizon, not the Doe Defendant."). There being no undue burden grounds available, Dr. Tully has no non-frivolous basis to seek Rule 45(d)(1) sanctions.

Finally, the remedy for any legitimate privacy concern is a protective order, not the complete discovery bar you have insisted upon. Plaintiff has no intention of using the information obtained from the subpoena for any use other than for its application to the litigation, and is open to

discussing an appropriate confidentiality agreement.

Best, Brad

From: Rich, Joshua < <u>rich@mbhb.com</u>>

Sent: Wednesday, November 16, 2022 4:40 PM **To:** Bradley J. Demuth < bdemuth@faruqilaw.com>

Cc: Rae, Jacob M. <<u>iacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

CAUTION: This Message originated from outside of the firm. Do not click on a link, open or enable any file unless you trust the sender.

Counsel,

We appear to have received no response to the message set forth below (if the response was misdirected or caught in our spam filter, please let me know immediately and re-send the response).

If no response was sent, it then appears that Plaintiff is unwilling to identify any legal basis for the extreme breadth of its subpoena and is unwilling to withdraw the subpoena (potentially to narrow the request in light of the corrected information set forth below). That is unfortunate. It is also improper under Rule 45, and would subject Plaintiff (and its counsel) to the possibility of sanctions under Rule 45(d)(1).

In the absence of a substantive, reasonable response, we believe that we have no choice but to file a motion to quash the subpoena on Dr. Tully's behalf. Given that the subpoena was served upon AT&T Wireless in North Palm Beach, Florida, the motion may be filed in the first instance in the Southern District of Florida. However, the comments to Rule 45 indicate that "In new Rule 45(f), the party consent feature was removed, meaning consent of the person subject to the subpoena is sufficient to permit transfer to the issuing court." We will reach out to AT&T Wireless to find their preference as to the venue of resolution of the motion.

Regards,

Joshua Rich



300 S. Wacker Drive | Chicago, IL 60606 Mansfield Rule Participating Firm

From: Rich, Joshua

Sent: Tuesday, November 15, 2022 3:55 PM

To: Bradley J. Demuth < <u>bdemuth@farugilaw.com</u>>

Cc: Rae, Jacob M. < <u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

Counsel,

Plaintiff seems to have a fundamental misunderstanding of the factual situation involved here. The phone number that underlies the subpoena (at least the portion related to Dr. Tully) is for Dr. Tully's personal cell phone. He used it from time to time for business calls, but it is primarily his personal number (as you know from his testimony in deposition).

Under these circumstances, we believe it is clear that Dr. Tully has a privacy interest in not only his personal call information and location identification (in which the Supreme Court found an individual would have a privacy interest in *Carpenter v. US*), but also calls and texts with any business contacts unrelated to this case. Plaintiff has no good faith basis for wanting to see any of that information, and the only purpose of drafting a subpoena so broadly as to capture it all would be to seek to harass, abuse, or embarrass Dr. Tully. Such a broad request is unjustifiable under Rule 26, let alone Rule 45's requirement that "[a] party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena."

We further note that we disagree completely with Plaintiff's assertion that it had no obligation to alert Dr. Tully to the service of a subpoena seeking his personal information. That intentional lack of notice is a further reason why the subpoena is improper.

We hope these points clear up Plaintiff's misunderstandings. Please let us know if Plaintiff will withdraw the subpoena in light of the more accurate recitation of facts here. Please let us know by 10 a.m. EST tomorrow.

Regards,

Joshua Rich

logo



Joshua Rich | Partner and General Counsel d: 312.913.2133 | o: 312.913.0001 300 S. Wacker Drive | Chicago, IL 60606 Mansfield Rule Participating Firm

From: Bradley J. Demuth < bdemuth@farugilaw.com >

Sent: Monday, November 14, 2022 7:18 PM

To: Rich, Joshua < rich@mbhb.com >

Cc: Rae, Jacob M. < <u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<alexandra.russell@kirkland.com>; bfee@morganlewis.com; DiMattio, Melina R.

<melina.dimattio@morganlewis.com>; ColcrysPlaintiffs <<u>ColcrysPlaintiffs@garwingerstein.com</u>>

Subject: RE: Value Drug v. Takeda: Subpoena upon AT&T Wireless

Mr. Rich: Thank you for your email but we will not be withdrawing the duly noticed subpoena for phone records Plaintiff served on AT&T.

Dr. Tully has no cognizable privacy interest in AT&T's records concerning the numbers from which Dr. Tully sent and received communications. The AT&T phone number for Dr. Tully at issue in the subpoena, (847) 910-7092, is not a "home number" as you represent below, but is instead the cell phone number Dr. Tully regularly identified in his work email signature block and the one he used to make at-issue communications throughout the 2015-2019 time period specified in the subpoena.

Plaintiff alleges a conspiracy hatched in 2015 in which Dr. Tully's communications played a part, and Dr. Tully continued to have a role in relevant events up through Mylan's launch in December 2019.

In sum, there is nothing improper about the subpoena or its temporal scope.

If there is something legitimately embarrassing Dr. Tully expects will be revealed by the AT&T phone records, Plaintiff is happy to meet and confer to discuss those issues further.

Best, Brad

From: Rich, Joshua < rich@mbhb.com>

Sent: Monday, November 14, 2022 8:16 AM

To: Bradley J. Demuth < <u>bdemuth@farugilaw.com</u>>

Cc: Rae, Jacob M. <<u>jacob.rae@kirkland.com</u>>; Russell, Alexandra I.

<a href="mailto:salpare:salp

Subject: Value Drug v. Takeda: Subpoena upon AT&T Wireless

CAUTION: This Message originated from outside of the firm. Do not click on a link, open or enable any file unless you trust the sender.

Counsel:

Over the weekend, AT&T Wireless informed Dr. Tully that Value Drug had served a subpoena dated October 28 upon it, seeking almost five years of phone records for Dr. Tully's personal cell phone (as well as information related to other individuals). As you know, we serve as Dr. Tully's counsel in relation to this matter. Yet we are unaware of any effort by Value Drug to notify us of the issuance or service of the subpoena upon AT&T Wireless.

First, please identify any efforts that Value Drug took to notify Dr. Tully of the subpoena seeking his personal phone records, either directly or through counsel. If none were made, please explain why Value Drug failed to make any effort to inform him of a subpoena that would have direct effect on his privacy.

Second, the subpoena is incredibly overbroad attempt to delve into Dr. Tully's personal records over a scope and time period seemingly unrelated to the underlying litigation. As Value Drug knows, the telephone number that is the subject of the subpoena is Dr. Tully home number, not his business telephone number. Further, there is no relationship between the time period specified in the subpoena (almost five years extending from the middle of the underlying litigation to over two years after its settlement) and anything relevant to this case. There is no attempt to tailor the inquiry to preserve Dr. .Tully's privacy whatsoever – the subpoena asks about every call he made from his personal number. Such a broad invasion of Dr. Tully's privacy can only be seen as an attempt to intimidate and embarrass him with the potential disclosure of his personal information.

Under these circumstances, we ask that Value Drug withdraw the subpoena immediately (at least as it pertains to Dr. Tully) and provide the information requested above by the close of business today. Please provide written notice of having done so as well, but the close of business today.

Regards,

Joshua Rich





Joshua Rich | Partner and General Counsel d: 312.913.2133 | o: 312.913.0001 300 S. Wacker Drive | Chicago, IL 60606 Mansfield Rule Participating Firm

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.) NOTICE: Attorneys MUST Indicate All Re-filed Cases Below.

I. (a) PLAINTIFFS V	DEFENDANTS .TAKEDA PHARMACEUTICALS, U.S.A., INC., et al.,							
(b) County of Residence of First Listed Plaintiff Blair (EXCEPT IN U.S. PLAINTIFF CASES)			County of Residence of First Listed Defendant (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF					
(a) Au an an a				THE TRAC	T OF LAND INVOLV		LOCATI	OIV OI
(c) Attorneys (Firm Name, A			Attorneys (If Known					
Faruqi & Faruqi, LLF	Kirkland & Ellis I 300 North LaSallo Chicago, IL 6060	e 54						
(d) Check County Where Actio	n Arose: MIAMI- DADE	☐ MONROE ☐ BROWARD ☐	PALM BEACH MARTIN ST. LU	UCIE 🗖 INDIAN	RIVER OKEECHOBE	EE HIGHLAND	S	
II. BASIS OF JURISDI	CTION (Place an "X" is	n One Box Only)	. CITIZENSHIP OF F	PRINCIPA	L PARTIES (P	lace an "X" in O	ne Box for	· Plaintiff)
П 1 ИС С	E-1		(For Diversity Cases Only)		and One Box fo	or Defend	ant)
U.S. Government Plaintiff	(U.S. Government	eral Question Not a Party)		PTF DEF ☐ 1 ☐ 1	Incorporated or Prin of Business In This		PTF ☐ 4	DEF ☐ 4
2 U.S. Government Defendant		ersity ip of Parties in Item III)	Citizen of Another State	□ 2 □ 2	Incorporated and Proof Business In A	-	□ 5	□ 5
			Citizen or Subject of a Foreign Country	3 3	Foreign Nation		□ 6	□ 6
IV. NATURE OF SUIT		aly) C	Click here for: Nature of Suit Code FORFEITURE/PENALTY		NKRUPTCY	ОТЦЕР	STATU	FEC
110 Insurance	PERSONAL INJURY	PERSONAL INJURY	625 Drug Related Seizure		eal 28 USC 158	375 False C		
☐ 120 Marine ☐ 130 Miller Act	☐ 310 Airplane ☐ 315 Airplane Product	☐ 365 Personal Injury - Product Liability	of Property 21 USC 881 ☐ 690 Other	☐ 423 Witi		376 Qui Ta 3729 (a))	m (31 US	С
☐ 140 Negotiable Instrument ☐ 150 Recovery of Overpayment	Liability ☐ 320 Assault, Libel &	☐ 367 Health Care/ Pharmaceutical		PROP	ERTY RIGHTS	 □ 400 State R ■ 410 Antitru 	st	
& Enforcement of Judgment 151 Medicare Act	Slander ☐ 330 Federal Employers'	Personal Injury Product Liability		☐ 820 Cop ☐ 830 Pate		☐ 430 Banks ☐ 450 Comm		ing
☐ 151 Medicale Act ☐ 152 Recovery of Defaulted	Liability	☐ 368 Asbestos Personal		835 Pate	nt – Abbreviated	☐ 450 Comm		
Student Loans	340 Marine	Injury Product Liabil	ity	840 Trac 880 Def	Drug Application lemark and Trade Secrets	☐ 470 Racke		enced and
(Excl. Veterans)	345 Marine Product		LABOR	- Act of	2016 AL SECURITY	- 480 Consur	ner Credi	t
☐ 153 Recovery of Overpayment	Liability	PERSONAL PROPERTY	☐ 710 Fair Labor Standards	□ 861 HIA		485 Teleph	1681 or 1 one Consi	1692) umer
of Veteran's Benefits 160 Stockholders' Suits 190 Other Contract 195 Contract Product Liability 196 Franchise	☐ 350 Motor Vehicle ☐ 355 Motor Vehicle Product Liability ☐ 360 Other Personal Injury ☐ 362 Personal Injury -	☐ 370 Other Fraud ☐ 371 Truth in Lending ☐ 380 Other Personal Property Damage ☐ 385 Property Damage Product Liability	Act 720 Labor/Mgmt. Relations 740 Railway Labor Act 751 Family and Medical Leave Act 790 Other Labor Litigation	☐ 862 Blac	ck Lung (923) VC/DIWW (405(g)) D Title XVI	Protection Act (TCPA) 490 Cable/Sat TV 850 Securities/Commodities/ Exchange 890 Other Statutory Actions 891 Agricultural Acts 893 Environmental Matters		
REAL PROPERTY 210 Land Condemnation 220 Foreclosure 230 Rent Lease & Ejectment	Med. Malpractice CIVIL RIGHTS 440 Other Civil Rights 441 Voting 442 Employment	PRISONER PETITIONS Habeas Corpus: 463 Alien Detainee 510 Motions to Vacate Sentence	791 Empl. Ret. Inc. Security Act	FEDERAL TAX SUITS □ 870 Taxes (U.S. Plaintiff or Defendant) □ 871 IRS—Third Party 26 US 7609		895 Freedom of Information Act 896 Arbitration 899 Administrative Procedure		
☐ 240 Torts to Land ☐ 245 Tort Product Liability ☐ 290 All Other Real Property	☐ 443 Housing/ Accommodations ☐ 445 Amer. w/Disabilities - Employment ☐ 446 Amer. w/Disabilities - Other ☐ 448 Education	Other: 530 General 535 Death Penalty 540 Mandamus & Other 550 Civil Rights 555 Prison Condition 560 Civil Detainee – Conditions of Confinement	IMMIGRATION ☐ 462 Naturalization Application ☐ 465 Other Immigration Actions	on		Statutes	iutionalit	y of State
1 Original 2 Remo from S Court		Reinstated 5 Transfer another (specify,		Dis from Jud	m Magistrate - gment l	Multidistrict □9 Litigation □9 – Direct File	Remano Appella	ded from ate Court
VI. RELATED/ RE-FILED CASE(S)	(See instructions): a) JUDO	Re-filed Case □YES GE: Honoarable Mark		Cases ■YE DO	S □ NO CKET NUMBER:	2:21-cv-03	500 (El	DPA)
VII. CAUSE OF ACTIO	227	, 15(a); Conspiracy in	ling and Write a Brief Statem restraint of trade, mono for both sides to try entire cas	polization,	·		ess divers	ity):
VIII. REQUESTED IN COMPLAINT:	\Box CHECK IF THIS UNDER F.R.C.P.	IS A CLASS ACTION 23	DEMAND \$	(CHECK YES only i	f demanded in	complai	nt:
ABOVE INFORMATION IS	TRUE & CORRECT TO			JU	RY DEMAND:	☐ Yes	■ No	
DATE November 18, 2022		SIGNATURE OF A'	ITORNEY OF RECORD					
FOR OFFICE USE ONLY : RECI	EIPT# AMO		JUDGE		MAG JUDGE			

INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I. (a) **Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- **II. Jurisdiction**. The basis of jurisdiction is set forth under Rule 8(a), F.R.C.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.

United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.

United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.

Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked. Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; federal question actions take precedence over diversity cases.)

- **III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- **IV. Nature of Suit.** Nature of Suit. Place an "X" in the appropriate box. If there are multiple nature of suit codes associated with the case, pick the nature of suit code that is most applicable. Click here for: Nature of Suit Code Descriptions.
- V. Origin. Place an "X" in one of the seven boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.

Refiled (3) Attach copy of Order for Dismissal of Previous case. Also complete VI.

Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.

Transferred from Another District. (5) For cases transferred under Title <u>28 U.S.C. Section 1404(a)</u>. Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.

Appeal to District Judge from Magistrate Judgment. (7) Check this box for an appeal from a magistrate judge's decision.

Remanded from Appellate Court. (8) Check this box if remanded from Appellate Court.

- VI. Related/Refiled Cases. This section of the JS 44 is used to reference related pending cases or re-filed cases. Insert the docket numbers and the corresponding judges name for such cases.
- VII. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. Do not cite jurisdictional statutes unless diversity. Example: U.S. Civil Statute: 47 USC 553

Brief Description: Unauthorized reception of cable service

VIII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.

Demand. In this space enter the dollar amount (in thousands of dollars) being demanded or indicate other demand such as a preliminary injunction.

Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.

Date and Attorney Signature. Date and sign the civil cover sheet.